• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/10/21 10:57:21 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HEPA alert in real time by email
    SC 13G 1 tv01050-hepionpharmaceutical.htm SCHEDULE 13G hepionpharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Hepion Pharmaceuticals Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  426897104

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  426897104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    6,383

    7.  SOLE DISPOSITIVE POWER

    1,722,221

    8.  SHARED DISPOSITIVE POWER

    6,383

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,728,604

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.96%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Hepion Pharmaceuticals Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    399 Thornall Street, First Floor
    Edison, New Jersey 08837

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    426897104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    1,728,604

      (b) Percent of Class:

    5.96%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  6,383

    (iii)  sole power to dispose of or to direct the disposition of:  1,722,221

    (iv)  shared power to dispose or to direct the disposition of:  6,383

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $HEPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HEPA

    DatePrice TargetRatingAnalyst
    2/28/2022$3.50Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HEPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Purcell Michael J.

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      3/7/24 4:15:14 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Purcell Michael J.

      3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      3/6/24 4:30:41 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Jacob Gary S

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      2/21/24 8:01:44 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

      SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      11/14/24 4:07:59 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Hepion Pharmaceuticals Inc.

      SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      2/14/24 3:38:57 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      2/14/22 6:05:01 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

      MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shar

      5/12/25 4:30:00 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

      MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it has entered into a binding letter of intent ("LOI") with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time. The di

      5/7/25 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Announces Reverse Stock Split

      Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m. Eastern Time on March 17, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on March 18, 2025, and will continue to trade on The Nasdaq Capital

      3/14/25 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Hepion Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50

      2/28/22 8:01:07 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wijngaard Peter bought $15,350 worth of shares (5,000 units at $3.07), increasing direct ownership by 111% to 9,501 units (SEC Form 4)

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      11/28/23 6:55:05 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Wijngaard Peter bought $16,841 worth of shares (3,000 units at $5.61), increasing direct ownership by 200% to 4,501 units

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      9/20/23 11:27:22 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Foster Robert T bought $8,960 worth of shares (1,600 units at $5.60), increasing direct ownership by 3% to 50,470 units

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      9/19/23 9:01:30 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.

      10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

      5/19/25 5:30:01 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Hepion Pharmaceuticals Inc.

      SCHEDULE 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      5/15/25 5:23:33 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Hepion Pharmaceuticals Inc.

      NT 10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

      5/15/25 4:30:28 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Leadership Updates

    Live Leadership Updates

    See more

    $HEPA
    Financials

    Live finance-specific insights

    See more
    • Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

      EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified p

      3/6/24 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theralase(R) Announces Appointment of New Independent Director

      TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco's Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one o

      6/6/23 7:00:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

      EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced the appointments of Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its Board of Directors, effective immediately. "We are thrilled to welcome individuals of this caliber to our Board," said Hepion's Chairman, Gary S. Jacob, Ph.D. "Mr. Reddi and Dr. Lbiati have a remarkable wealth of experience across all aspects of drug development, from clinical research to med

      6/28/22 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

      - Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t

      11/13/23 4:05:00 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

      EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the

      11/10/23 8:50:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

      - Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl

      5/22/23 7:00:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care